Kyselina Zoledrónová Sandoz

Zoledronic acid, the active ingredient in Kyselina Zoledrónová Sandoz, is a bisphosphonate presented as a sterile intravenous solution for infusion use. It is employed to treat postmenopausal osteoporosis, Paget's disease of bone, bone metastases, and hypercalcemia of malignancy.

GNH USA supplies Kyselina Zoledrónová Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier, ensuring quality and regulatory compliance for hospitals, oncology centres and pharmacies worldwide. The product conforms to EU standards and is distributed through validated cold‑chain logistics, supporting safe clinical use.

Zoledronic acid is a bisphosphonate used to manage disorders of bone remodeling.

Postmenopausal osteoporosis: reduces risk of vertebral and hip fractures by inhibiting bone resorption. Paget's disease of bone: normalizes abnormal bone turnover and alleviates bone pain. Bone metastases: decreases skeletal-related events and bone pain in cancer patients. Hypercalcemia of malignancy: rapidly lowers elevated serum calcium levels.

Adverse reactions may occur with zoledronic acid therapy.

Common Side Effects: - Acute‑phase reaction (fever, myalgia, arthralgia) - Nausea or vomiting - Transient renal function changes - Headache

Serious or Rare Side Effects: - Renal toxicity requiring monitoring - Osteonecrosis of the jaw - Severe hypocalcemia

Key safety considerations should be observed before and during treatment.

Renal function assessment: evaluate baseline creatinine and eGFR prior to infusion. Calcium and vitamin D status: correct deficiencies before administration. Concurrent nephrotoxic drugs: avoid or monitor closely. History of jaw surgery or dental procedures: consider risk of osteonecrosis. Store at ambient temperature: keep in original container, protect from light and moisture.

Zoledronic acid may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Concurrent use of other bisphosphonates: increased toxicity risk. - Aminoglycoside antibiotics: potentiate renal impairment. - High‑dose NSAIDs: may worsen renal function.

Moderate Interactions (Monitor Closely): - Calcium supplements: may reduce drug efficacy; separate administration by at least 30 minutes. - Vitamin D analogues: monitor serum calcium levels. - Loop diuretics: increase risk of hypocalcemia.